ReviewClinical journal of oncology nursing2025
Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma.
Review in Clinical journal of oncology nursing, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.Oncology research · 2026Review
- Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), alone or in combination with immune checkpoint inhibitors, are part of the standard of care in treating metastatic renal cell carcinoma (mRCC). VEGFR-TKIs are associated with acute, chronic, and potentially dose-limiting toxicities requiring treatment modifications and discontinuations.
objectivesThis article summarizes evidence-based practices that oncology nurses may use to manage VEGFR-TKI adverse events and improve quality of life in patients with mRCC.
methodsPivotal clinical trial publications of VEGFR-TKIs in mRCC were reviewed to evaluate the adverse event profile of each drug and effective management strategies.
findingsPatients with mRCC treated with VEGFR-TKIs can benefit from education about potential side effects, consistent monitoring, and early detection of adverse events, as well as appropriate interventions to improve treatment tolerability, adherence, outcomes, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.